This "hot Stocked" paragraph written by Kaloyan Gadzhev does not help:
"The fact that the company is very far from profitable doesn't prevent it from paying its executives hefty sums. Gary Rabin, CEO of ACTC, got nearly $3.6 million in 2011. The Chief Scientific Office, Robert Lanza, M.D., got about $3.5 million. Approximately two-thirds of those amounts were in stock awards or stock options, which doesn't help the dilution issue."